Epoxomicin

Epoxomicin (BU-4061T) is an epoxyketone-containing natural product and a potent, selective and irreversible proteasome inhibitor. Epoxomicin covalently binds to the LMP7, X, MECL1, and Z catalytic subunits of the proteasome and potently inhibits primarily the chymotrypsin-like activity. Epoxomicin can cross the blood-brain barrier. Epoxomicin has strongly antitumor and anti-inflammatory activity[1][2][3][4][5].

Product Specifications

CAS Number

[134381-21-8]

Product Name Alternative

BU-4061T

UNSPSC

12352005

Target

Apoptosis; Proteasome

Type

Natural Products

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Epoxomicin.html

Purity

99.60

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C([C@@H](NC([C@H]([C@@H](C)O)NC([C@@H](NC([C@H]([C@@H](C)CC)N(C)C(C)=O)=O)[C@@H](C)CC)=O)=O)CC(C)C)[C@@]1(C)CO1

Molecular Formula

C28H50N4O7

Molecular Weight

554.72

References & Citations

[1]Kim KB, et al. Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency. Bioorg Med Chem Lett. 1999 Dec 6;9 (23) :3335-40.|[2]Hanada M, et al. Epoxomicin, a new antitumor agent of microbial origin. J Antibiot (Tokyo) . 1992 Nov;45 (11) :1746-52.|[3]Garrett IR, et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest. 2003 Jun;111 (11) :1771-82.|[4]McNaught KS, et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol. 2004 Jul;56 (1) :149-62.|[5]Meng L, et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A. 1999 Aug 31;96 (18) :10403-8.